Purchase Order HHSN261201700565P

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $6,750.00 on August 29, 2017, with completion scheduled for September 30, 2017. Performance is located in San Diego, California. The order covers DNA services using Adaptive's immunosequencing capabilities. This is a firm fixed-price acquisition with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $4,662.50 on July 20, 2017, for DNA extraction services. Place of performance is Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of August 18, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $3,550.00 on November 14, 2017, with ultimate completion on December 14, 2017. Place of performance is Piscataway, New Jersey. The order procures DNA services under firm fixed-price terms without set-aside designation.</p>

<p>The National Cancer Institute awarded a $6,950 purchase order to Adaptive Biotechnologies Corporation on August 30, 2017 for DNA services using adaptive biotechnologies and CAFRI methodologies. Work is performed in Piscataway, New Jersey, with an ultimate completion date of September 30, 2017. The order is firm fixed-price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $5,087.50 on January 24, 2018, with ultimate completion on February 24, 2018. Work is performed in Piscataway, New Jersey. The order covers DNA services under firm fixed-price pricing with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $9,987.50 on January 4, 2018, with completion scheduled for February 4, 2018. Work is performed in Piscataway, New Jersey. The order covers DNA services and adaptive biotechnology testing. Pricing is firm fixed price.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $13,350.00 on December 27, 2018, for DNA extraction service, domestic shipping, and TCRB V4 service deep and survey work. Work is performed in Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of February 28, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $197,125 on July 22, 2014, covering service delivery of 40,000 input genomes and 200,000 TCR sequences survey work. Place of performance is Bethesda, Maryland. The order carries a firm fixed-price structure with an ultimate completion date of April 23, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $10,212.50 on August 12, 2019, for lab testing services. Performance concludes September 11, 2019, with work performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $11,930.00 on August 2, 2018, with an ultimate completion date of September 28, 2018. Work is performed in Seattle, Washington. The order procures immunosequencing services and diagnostic testing delivered under firm fixed-price pricing.</p>